Appendix B. Base case analysis results of the semi-Markov model using flexible parametric models within a relative survival framework (semi-Markov: FPMs, RSF).

| Parameter | RFC | FC | Incremental |
| --- | --- | --- | --- |
| Mean life years | 6.84 | 6.70 | 0.13 |
| Mean life years PFS | 3.84 | 2.81 | 1.03 |
| Mean life years progression | 3.00 | 3.89 | -0.89 |
| Mean QALYs | 4.87 | 4.59 | 0.28 |
| Mean QALYs PFS | 3.07 | 2.25 | 0.82 |
| Mean QALYs progression | 1.80 | 2.34 | -0.54 |
| Mean total costs | £ 26392 | £ 16629 | £ 9763 |
| Mean costs of PFS | £ 18874 | £ 6854 | £ 12020 |
| Mean costs of progression | £ 7518 | £ 9775 | £ -2258 |
| Cost per life year gained |  |  | £ 72836 |
| Cost per QALY gained |  |  | £ 34511 |
| FC, fludarabine and cyclophosphamide; RFC, rituximab, fludarabine, and cyclophosphamide; QALY, quality-adjusted life year; PFS, progression-free survival. | | | |